D apsone (4,4' diaminodiphenysulphone) was first synthesized in 1908. Aside from leprosy, it has been used for the treatment of many other dermatologic and nondermatologic conditions.
Although adverse reactions such as methemoglobinemia, hemolytic anemia, agranulocytosis, and hypersensitivity reactions have been well recognized, 1,2 the characteristics of as well as the mechanisms underlying the hepatic injury associated with the use of dapsone remain unclear.
We systematically analyzed the diverse clinical and laboratory characteristics as well as outcomes of patients with dapsone related hepatotoxicity from a single center. In addition, we summarized the findings from published reports on dapsone-induced hepatitis (DIH).
Methods
We analyzed the clinical and laboratory characteristics and outcomes of all cases of DIH among cases of drug-induced liver injury (DILI) evaluated at St. John's Medical College Hospital, Bangalore, India (retrospective, 1997-2004; prospective, 2005-2016) . The details of DILI registry and definitions used were reported earlier. 3 The liver injury patterns and severity were defined as per international guidelines and included hyperbilirubinemia (bilirubin level, >2 mg/dL), coagulopathy (international normalized ratio [INR] > 1.5), ascites, encephalopathy, or death. 4 Acute liver failure (ALF) was defined as per standard criteria. 5 Causality was assessed with the Roussel Uclaff causality assessment method. 6 After dapsone was discontinued, most patients received either intravenous hydrocortisone or oral prednisolone 0.5 to 1 mg per kg body weight (tapered over 4-6 weeks). Skin rashes were treated with topical emollients and antibiotics, conjunctivitis was treated with antibiotic eye drops, and mouth washes were used for the management of oral ulcerations. The study was approved by the institutional ethics committee.
We systematically reviewed PubMed and Scopus (1949 to June 2016), including references from reviewed articles for information on DIH.
Statistical Analysis
Variables were summarized as means/medians and SD for continuous variables and as frequencies and percentages for categoric variables. The chi-square test and the Student t test were used to evaluate categorical and continuous variables, respectively. A P value less than .05 was considered significant.
Results
We identified 44 cases of DIH among 850 patients with DILI, constituting 5.2% of all cases. The clinical, demographic, and laboratory characteristics at presentation are summarized in Table 1 . The mean treatment duration before the onset of liver injury was 34 days (range, 8-150 d). More than 90% of patients showed hypersensitivity features such as skin rashes, lymphadenopathy, fever, and/or eosinophilia. Jaundice, encephalopathy, ascites, and an increased INR (>1.5) were seen in 63%, 16%, 11.4%, and 24%, respectively.
The liver injury patterns in 43 patients were as follows: 34% hepatocellular (n ¼ 15), 16% cholestatic (n ¼ 7), and 48% mixed (n ¼ 20). According to the Roussel Uclaff causality assessment method, 25 (57%) were considered definite, 14 (32%) were considered probable, and 5 (11%) were considered possible.
Seven patients (16%) presented with ALF, of whom 2 died. Three additional patients died of multiorgan failure, which included 1 patient with a skin injury. Other significant complications included methemoglobinemia, agranulocytosis (rescued with granulocyte colonystimulating factor), and Coombs-positive hemolytic anemia (rescued with methylprednisolone) were noted in 1 patient each.
Literature Review
We identified 72 cases (females > males) of DIH published between 1949 and 2015, that fulfilled DILIdefining criteria. 4 The liver was the most common extradermatologic organ involved in dapsone hypersensitivity syndrome (DHS). DHS as a key feature of DIH was identified in 64 of 72 patients (88.8%). The latency period was 31.8 days (range, 7-150 d). Dapsone rechallenge in a third of the patients resulted in DHS/ DIH with shortened latency and severe disease including death. The mean bilirubin level was 8. Where treatment details were available (n ¼ 38), most patients (n ¼ 28) had been treated with steroids, leading to faster recovery and lower mortality than those not receiving steroids. The overall mortality rate was 19.4% (14 of 72 patients). One patient required a liver transplantation. 7 
Discussion
DIH can vary from mild (which resolves with discontinuation of drug alone) to severe liver injury including ALF and death. Mixed hepatitis is the most common pattern of liver injury. Severity indices such as jaundice, encephalopathy, ascites, and an increased INR (>1.5) was seen in 62%, 16.7%, 12%, and 24%, respectively. The mortality rate was 12% in our series and 19% in the published literature.
DIH occurs mostly within the first 4 to 6 weeks of therapy and shows 2 distinctive subtypes: the vast majority (90%) are associated with DHS, and a minority (10%) that lack DHS. Immunoallergic features that characterize DHS such as skin reactions, fever, lymphadenopathy, and eosinophilia tend to overshadow features of liver injury and probably have contributed to under-recognition of hepatitis and an underestimation of its severity. 8 Paradoxically, immunoallergic features may offer a clue to early diagnosis of DIH.
In conclusion, the near-universal presence of hypersensitivity features (90%) with DIH is consistent with immune-mediated liver injury and this in turn lends itself to early diagnosis, and, when treated with steroids, to significant recovery. 
